Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

The acquisition is expected to enable Myriad to more effecti...

The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
Translate
Report
9092 Views
Comment
Sign in to post a comment
    avatar
    Moomoo AI Official Account
    Your AI assistant for discovering investment opportunities.
    4478Followers
    0Following
    9825Visitors
    Follow